Routine Ophthalmological Examination Rates in Adults with Sickle Cell Disease Are Low and Must Be Improved

Author:

Zulueta Patricia1,Minniti Caterina P.1,Rai Anvit1,Toribio Tiana J.23,Moon Jee-Young4,Mian Umar K.23ORCID

Affiliation:

1. Albert Einstein College of Medicine, New York, NY 10461, USA

2. Department of Ophthalmology & Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA

3. Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA

4. Department of Epidemiology & Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA

Abstract

The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.

Funder

Office of Medical Student Research at the Albert Einstein College of Medicine

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference17 articles.

1. Ischemia-Reperfusion Injury in Sickle Cell Disease;Ansari;Am. J. Pathol.,2019

2. Feroze, K.B., and Azevedo, A.M. (2022, January 10). Retinopathy Hemoglobinopathies, StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK441850/.

3. Patterns of Visual Loss in Untreated Sickle Cell Retinopathy;Moriarty;Eye.,1988

4. Akhter, M., Latting, M.W., and Scott, A.W. (2021, July 02). Ophthalmic Pearls: Management of proliferative sickle cell retinopathy [Internet]. San Francisco (CA): EyeNet Magazine; 2018 October [cited 2022 March 5]. Available online: https://www.aao.org/eyenet/article/proliferative-sickle-cell-retinopathy.

5. Awareness of Ocular Manifestations, Complications, and Treatment of Sickle Cell Disease in the Eastern Province of Saudi Arabia: A Cross-Sectional Study;Alshehri;Middle East Afr. J. Ophthalmol.,2019

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Seltene vaskuläre Erkrankungen der Netzhaut – Teil 1;Klinische Monatsblätter für Augenheilkunde;2023-08-16

2. Seltene vaskuläre Erkrankungen der Netzhaut – Teil 1;Augenheilkunde up2date;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3